Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Clin Cancer Res. 2017 Mar 31;23(15):4335–4346. doi: 10.1158/1078-0432.CCR-16-2955

Figure 3. Radium-223 suppresses pathological bone formation in LNCaP and LuCaP 58 models of prostate cancer growth in mice.

Figure 3

A, Representative MGT staining of bone architecture and tumor area in LNCaP and LuCaP 58 tumor-bearing mice treated with vehicle or Radium-223 (300 kBq/kg, i.v.). Turquoise indicates bone, pale pink tumor and dark pink bone marrow. Scale bar = 1 mm; 25x magnification. B, Total bone area in mice bearing LNCaP tumors (n = 12–13, p = 0.00059). C, Total bone area in mice bearing LuCaP 58 tumors (n = 11, p = 0.05883). D, Trabecular bone area relative to bone marrow area in mice bearing LNCaP tumors (n = 12–13, p = 0.43710). E, Trabecular bone area relative to bone marrow area in mice bearing LuCaP 58 tumors. (n = 11, p = 0.0212). F, The number of osteoblasts relative to bone surface in mice bearing LNCaP tumors (n = 12–13, p = 0.00127). G, The number of osteoblasts relative to bone surface in mice bearing LuCaP 58 tumors (n = 11, p = 0.0014). H, The number of osteoclasts relative to tumor-bone interface (TBI) in mice bearing LNCaP tumors (n = 6–10, p = 0.01207). I, The number of osteoclasts relative to TBI in mice bearing LuCaP 58 tumors (p = 8–11, 0.19644). In box plots, horizontal lines show 5th, 25th, 50th, 75th and 95th centiles and crosses indicate mean values. ns = not significant,* p<0.05, ** p<0.01, *** p<0.001.